

# Does the Presence of Extended Jugular Lymphatic Sacs Add More Risk to Nuchal Thickness for Genetic and Structural Abnormality?

Mehmet Obut<sup>1\*</sup>, Arife Akay<sup>2</sup>, Ibanoglu Can Müjde<sup>2</sup>, Özge Yucel Çelik<sup>1</sup>, Asya Kalayci Öncü<sup>2</sup>, Zuat Acar<sup>3</sup>, Erdal Seker<sup>4</sup>, Erkan Saglam<sup>1</sup>, Cantekin Iskender<sup>1</sup>

<sup>1</sup>Department of Perinatology, Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Ankara, Turkey, <sup>2</sup>Department of Gynecology and Obstetrics, Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Ankara, Turkey, <sup>3</sup>Department of Perinatology, Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey, <sup>4</sup>Department of Perinatology, Faculty of Medicine, Ankara University, Ankara, Turkey

## Abstract

**Background:** The risks added by extended jugular lymphatic sacs (EJLS) to increased nuchal translucency (NT) including genetic and structural abnormalities and pregnancy outcomes have not been previously investigated, which this study aims to investigate. **Methods:** The data of 155 singleton pregnancies with increased fetal NT ( $\geq 95^{\text{th}}$  percentile) of these 20 with fetal EJLS were evaluated retrospectively. Patients were stratified according to NT thickness such that  $\geq 95^{\text{th}}$  percentile - 3.5 mm, 3.6–4.4 mm, 4.5–5.4 mm, 5.5–6.4 mm,  $\geq 6.5$  mm, and grouped according to the presence of EJLS. Pregnancy outcomes, genetic and structural abnormalities were assessed by comparing EJLS with non-EJLS cases (n-EJLS). **Results:** Associated with NT, the incidence of the presence of EJLS increased with NT, from 4.5% at the  $\geq 95^{\text{th}}$  percentile - 3.5 mm to 30.8% when NT  $\geq 5.5$  mm. In the n-EJLS group, the proportion of fetuses with structural and genetic abnormalities increased as the measurement of NT increased. This correlation was not observed in the EJLS group. Compared to n-EJLS, cases with EJLS had a higher rate of fetal structural (38.5% vs. 75%,  $P = 0.003$ ) and genetic (18.5% vs. 45%,  $P = 0.005$ ) anomalies and a lower term live birth rate (59.3% vs. 15%,  $P < 0.001$ ). **Conclusion:** The increasing rate of EJLS was seen as NT increased. Compared to n-EJLS, the EJLS cases had a higher rate poor pregnancy outcomes and fetal genetic and structural abnormalities.

**Keywords:** Abnormal karyotype, cystic hygroma, jugular lymphatic sac, nuchal thickness, structural abnormality

## INTRODUCTION

Nuchal thickness (NT) is the ultrasonographic expression of subcutaneous fluid accumulation posterior to the neck of the fetus, whether the accumulation is septated and confined to the neck or encompasses the entire fetus.<sup>[1]</sup> Enlarged NT is defined as the measurement of vertical thickness in the mid-sagittal region of the fetus during the first trimester that is equal to or greater than the 95<sup>th</sup> percentile of the reference range.<sup>[1,2]</sup> The incidence of enlarged NT is 8.6%<sup>[3]</sup> and has been associated with various fetal genetic or structural abnormalities. However, enlarged NT can also occur in normal fetuses.<sup>[3-5]</sup> The pathophysiology of enlarged NT is not fully understood, but theories such as heart failure, alteration of extracellular matrix composition, and disorders of lymphangiogenesis have been proposed.<sup>[6,7]</sup> Studies have

shown that pregnancies with increased fetal NT have a higher rate of fetal structural abnormalities, including congenital heart defects and musculoskeletal abnormalities.<sup>[3]</sup> In addition, pregnancies with elevated fetal NT have been found to have an increased rate of adverse pregnancy outcomes, such as amniotic fluid abnormalities, preterm births, miscarriages, pregnancy terminations of pregnancy (TOP), intrauterine fetal death (IUFD), and a low rate of live births, even in those without genetic and chromosomal abnormalities.<sup>[5-8]</sup> The incidence of extended jugular lymphatic sacs (EJLS) in the normal pregnant population ranges from 1.6% to

**Address for correspondence:** Dr. Mehmet Obut, Department of Perinatology, Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Ankara, Turkey. E-mail: drmehmetobut@hotmail.com

Received: 27-12-2021 Revised: 05-03-2022 Accepted: 05-07-2022 Available Online: 09-11-2022

### Access this article online

#### Quick Response Code:



**Website:**  
<https://journals.lww.com/jmu>

**DOI:**  
10.4103/jmu.jmu\_225\_21

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** WKHLRPMedknow\_reprints@wolterskluwer.com


**How to cite this article:** Obut M, Akay A, Müjde IC, Çelik ÖY, Öncü AK, Acar Z, *et al.* Does the presence of extended jugular lymphatic sacs add more risk to nuchal thickness for genetic and structural abnormality? J Med Ultrasound 2023;31:119-26.

2.4%.<sup>[8-10]</sup> However, the incidence of EJLS in cases with increased NT is much higher, ranging from 23.5% (415 / 98) to 84.6% (22 / 26).<sup>[3-10]</sup> The most widely accepted theories to explain the NT increase are cardiac dysfunction/failure or venous congestion in the fetal head and neck,<sup>[9]</sup> alterations in extracellular matrix components,<sup>[10]</sup> conditions such as fetal anemia, infection, and hypoproteinemia,<sup>[11]</sup> and disorders of lymphangiogenesis.<sup>[12]</sup> However, these theories could not explain the reason for the localization of such thickening to the neck of the fetus or the transient nature of this finding. It has also remained unexplained why concomitant EJLS appeared simultaneously in some cases and not in others.<sup>[13]</sup> Furthermore, the significance of fetal EJLS remains to be elucidated.<sup>[3-5,14-18]</sup>

In this study, we aimed to investigate whether the presence of EJLS in the first trimester increases the risk of genetic and structural abnormalities and pregnancy outcome in cases with increased NT.

## MATERIALS AND METHODS

After approval by the Health Sciences University, Etlik Zübeyde Hanım Woman's Health Training and Research Hospital's Institutional Review Board (no: 11/30-2021), and obtained patient consent, we retrospectively searched medical records between January 2017 and January 2021 for cases with increased NT detected by routine first-trimester ultrasound (USG). We identified 230 such pregnancies, 22 of which were associated with EJLS. The cases with multiple pregnancies ( $n = 12$ ; 11 had twins and another had a triplet pregnancy) or incomplete data or follow-up ( $n = 73$ ) were excluded. Finally, 155 patients, 20 of whom had EJLS, were enrolled in the study [Figure 1]. We collected data on patients' demographic characteristics, first- and second-trimester combined test results, ultrasonographic findings, type of invasive tests, and genetic results. We retrieved the data on pregnancy outcomes, including abortion, IUFD, TOP, postnatal death, preterm birth, term birth, and live birth (T and L) from the hospital



**Figure 1:** Diagram of study follow-up

database. According to our clinical protocol, if a patient was found to have an elevated fetal NT or other abnormal findings on first-trimester USG screening, were examined in detail by a perinatologist who had at least 8 years of experience in obstetric USG evaluation using the Voluson E6 device (GE Healthcare GmbH and Co OG, Zipf, Austria). These were evaluated with both transvaginal (via a 7-MHz probe) and abdominal (via a 5-MHz probe) USG screening. USG findings included crown-rump length, NT and absent or reversed a-wave of the ductus venosus (DV), tricuspid regurgitation, jugular lymphatic sacs (JLS), fetal structural abnormalities, and minor markers such as fetal echogenic intracardiac focus and hypoechogenic intestines.

The presence of JLS was studied in the transverse plane of the fetus through the mandible and spinal cord and confirmed in the coronal and sagittal planes.<sup>[8]</sup> Invasive tests were offered in all pregnancies with elevated NT, the type of which was selected according to the gestational week in which the patients were admitted: chorionic villus sampling if between 11 and 14 weeks of gestation, amniocentesis if between 16 and 22 weeks of gestation, or postnatal karyotyping if beyond 22 weeks of gestation.

The presence of an echogenic intracardiac focus, hyperechogenic bowel, or absent nasal bone was considered a mild marker, whereas other fetal anomalies were considered severe. For cases with genetic or structural anomalies, the decision of TOP was made by the perinatology council.

We stratified cases with or without EJLS and according to their NT categories:  $\geq 95^{\text{th}}$  percentile - 3.5 mm, 3.5–4.4 mm; 4.5–5.4 mm, 5.5–6.4 mm, and  $\geq 6.5$  mm. Study variables, including patient characteristics, chromosomal or structural abnormalities, and pregnancy outcomes, were determined based on these subgroups.

## Statistical analysis

Statistical analysis was performed using SPSS (Statistical Package for the Social Sciences) 26 (SPSS Inc., Chicago, IL, USA). The distribution of parameters was assessed by Kolmogorov–Smirnov's normality tests. Descriptive analyses were given (using tables of frequencies for the categorical variables and using means and minimum–maximum values for the normally distributed variables). One-way analysis of variance was used for the normally distributed and Kruskal–Wallis test was used for the nonnormally distributed continuous data. Comparison of categorical variables was performed by the Chi-square test or the Fisher's exact test where appropriate. The correlation between fetal abnormalities, adverse pregnancy outcomes, and EJLS and NT was assessed using Spearman-Rho correlation.  $P < 0.05$  was considered statistically significant.

## RESULTS

The mean maternal age of the study population ( $n = 155$ ) was  $29.18 \pm 6.11$  and the majority of patients had a fetal NT  $< 5.5$  mm. The distribution of cases according to stratified NT was 43.2%

(*n* = 67), 27.7% (*n* = 43), 15.5% (*n* = 24), 8.4% (*n* = 13), and 5.2% (*n* = 8) in the ≥95<sup>th</sup> percentile - 3.5 mm, 3.6–4.4 mm, 4.5–5.4 mm, 5.5–6.4 mm, and ≥6.5 mm, respectively. There were 20 (12.9%) pregnancies with fetal ELJS. The lower rate of ELJS cases was seen in pregnancies with fetal NT <4.5 mm compared to those had ≥4.5 mm. The distribution of ELJS in NT groups was such that 4.5% (*n* = 3), 9.3% (*n* = 4), 29.2% (*n* = 7), 30.8% (*n* = 4), 25% (*n* = 2) in ≥95<sup>th</sup> percentile - 3.5 mm, 3.6–4.4 mm, 4.5–5.4 mm, 5.5–6.4 mm, and ≥6.5 mm, respectively. An increasing rate of fetal structural and genetic abnormalities was observed as the NT increased. Furthermore, the higher rate of abortion, TOP and a lower rate of live birth were observed as the fetal NT increased [Table 1].

Table 2 demonstrates fetomaternal characteristics and pregnancy outcomes of the non-EJLS (n-EJLS) cases. The majority of cases had a fetal NT <5.5 mm. The higher rate of poor pregnancy outcomes and the lower rate of T and L births were observed as NT increased in these cases. The overall T and L ratio was 59.3% (T and L birth ratio ranging from 68% in ≥95<sup>th</sup> percentile - 3.5 mm group to 0% in ≥6.5). In addition, the higher rate of fetal structural and karyotypic abnormality was seen as NT increased. The overall rate of karyotypic anomaly was 18.5% (ranging from 10.9% in

≥95<sup>th</sup> percentile - 3.5 mm group to 50% in ≥6.5). Followed cystic hygroma (*n* = 27, 20%), the most common structural abnormalities detected were cardiovascular system (CVS) (*n* = 15, 11.1%) and central nervous system (CNS) (*n* = 9, 6.7%). Although the increasing rate of cystic hygromas and CVS anomalies were seen as the NT increased, this correlation was not seen with CNS or other systems anomalies. We found structural abnormalities in 75% of cases with EJLS, with cystic hygromas being the predominant condition (40%). The EJLS cases with NT of 4.5–6.4 mm had the highest rate (100%) of structural abnormalities. Karyotypic abnormalities and TOP were found in 45% and 55% of EJLS cases, respectively. The highest rate of karyotypic abnormalities (100%) and TOP (100%) was found in those with NT of 3.6–4.4 mm [Table 3].

Compared to cases without EJLS, those with EJLS had significantly higher rates of abnormal fetal anatomy (38.5% vs. 75%, *P* = 0.003), karyotype (18.5% vs. 45%, *P* = 0.005), reversed a-wave in the DV (10.4% vs. 30%, *P* = 0.026), TOP (14.1% vs. 55%, *P* < 0.001), and a lower rate of T and L births (59.3% vs. 15.0%, *P* < 0.001). The predominant karyotypic abnormality in both groups, trisomy 21, was significantly more common in cases with EJLS than in those without EJLS (35.0% vs. 8.9%, *P* = 0.00) [Table 4].

**Table 1: Fetal and maternal features and pregnancy outcomes of all cases included in study**

Variable	NT					Total ( <i>n</i> = 155), <i>n</i> (%)
	≥95 <sup>th</sup> percentile- 3.5 mm ( <i>n</i> = 67), <i>n</i> (%)	3.6-4.4 mm ( <i>n</i> = 43), <i>n</i> (%)	4.5-5.4 mm ( <i>n</i> = 24), <i>n</i> (%)	5.5-6.4 mm ( <i>n</i> = 13), <i>n</i> (%)	≥6.5 mm ( <i>n</i> = 8), <i>n</i> (%)	
Maternal age (mean±SD)	27.8±5.77	28.6±6.84	31.67±5.68	31.8±8.24	30±6.35	29.18±6.11
Gravida (mean±SD)	2.09±1.28	2.56±1.55	2.54±1.47	3±1.41	2.38±1.69	2.38±1.42
Parity (mean±SD)	0.82±0.87	1.21±1.1	1.13±1.19	1.15±1.28	0.88±0.83	1±1.028
Abortus (mean±SD)	0.28±0.71	0.42±0.96	0.3±0.7	0.92±1.04	0.50±1.07	0.38±0.84
EJLS	3 (4.5)	4 (9.3)	7 (29.2)	4 (30.8)	2 (25)	20 (12.9)
Reverse a wave in DV	5 (7.5)	6 (14)	5 (20.8)	2 (14.4)	2 (20.4)	20 (12.9)
Fetal anatomy						
Normal	39 (58.2)	22 (51.2)	6 (25)	1 (7.7)	0	68 (43.9)
Abnormal	18 (26.9)	14 (32.6)	17 (70.8)	11 (84.6)	7 (87.5)	67 (43.2)
M.M	10 (14.9)	7 (16.3)	1 (4.2)	1 (7.7)	1 (12.5)	20 (12.9)
Fetal karyotype						
Refused	8 (11.9)	5 (11.6)	3 (12.5)	2 (15.4)	1 (12.5)	19 (12.3)
Normal	51 (76.1)	27 (62.8)	13 (54.2)	7 (53.8)	4 (50)	102 (65.8)
Abnormal	8 (11.9)	11 (25.6)	8 (33.3)	4 (30.8)	3 (37.5)	34 (21.9)
Invasive testing						
CVS	44 (65.7)	29 (67.4)	20 (83.3)	11 (84.6)	5 (62.5)	99 (63.8)
Amniocentesis	12 (17.9)	7 (16.3)	8 (33.3)	0	2 (25)	29 (18.7)
Postnatal karyotyping	1 (1.4)	1 (2.3)	2 (8.3)	0	0	4 (2.5)
Pregnancy outcome						
Abortion	7 (10.4)	4 (9.3)	3 (12.5)	3 (23.1)	2 (25)	19 (12.3)
TOP	6 (9)	8 (18.6)	6 (25)	5 (38.5)	5 (62.5)	30 (19.4)
IUFD	1 (1.5)	1 (2.3)	0	0	0	2 (1.3)
T and L	45 (67.2)	23 (53.5)	10 (41.7)	5 (38.5)	0	83 (53.5)
PD	2 (3)	3 (7)	3 (12.5)	0	0	8 (5.2)
PB	6 (9)	4 (9.3)	2 (5.3)	0	1 (12.5)	13 (8.4)

NT: Nuchal translucency, EJLS: Extended jugular lymphatic sac, SD: Standard deviation, DV: Ductus venosus, CVS: Chorionic villus sampling, M.M: Minor marker, TOP: Termination of pregnancy, IUFD: Intrauterine fetal death, T and L: Term and live birth, PD: Postnatal death, PB: Preterm delivery

**Table 2: Feto-maternal characteristics and pregnancy outcomes of nonextended jugular lymphatic sac cases**

Variables	NT					Total (n=135), n (%)
	≥95 <sup>th</sup> percentile- 3.5 mm (n=64), n (%)	3.6-4.4 mm (n=39), n (%)	4.5-5.4 mm (n=17), n (%)	5.5-6.4 mm (n=9), n (%)	≥6.5 mm (n=6), n (%)	
Maternal age (mean±SD)	28.08±5.23	28.57±5.58	31±6.46	33.6±7.16	29.3±4.68	29.07±5.96
Number of gravida (mean±SD)	2.13±1.19	2.56±1.56	2.47±1.5	3.11±1.36	2±0.89	2.38±1.44
Reverse a wave in DV	4 (6.3)	4 (10.3)	4 (23.5)	1 (11.1)	1 (16.7)	14 (10.4)
Fetal anatomy						
Normal	38 (59)	21 (53.8)	6 (35.3)	1 (11.1)	0	66 (48.9)
Abnormal	16 (25)	13 (33.3)	10 (58.8)	7 (77.8)	6 (100)	52 (38.5)
MM	10 (15)	5 (12.8)	1 (5.9)	1 (11.1)	0	17 (12.6)
Affected organs or systems						
CH	9 (14)	8 (20.5)	5 (29.4)	3 (33.3)	2 (33)	27 (20)
CNS	3 (4.7)	1 (2.6)	0	0	1 (16)	5 (3.7)
CVS	4 (6.3)	3 (7.7)	4 (23.5)	2 (22.2)	2 (33)	15 (11.1)
GIS	7 (10)	1 (2.6)	0	1 (11.1)	0	9 (6.7)
Hydropic placenta	0	0	1 (5.9)	0	0	1 (0.7)
MSS	0	1 (2.6)	0	0	1 (16)	2 (1.5)
Hypoplastic NB	1 (1.6)	0	0	0	0	1 (0.7)
SUA	0	2 (5.1)	0	0	0	2 (1.5)
Isolated HF	1 (1.6)	1 (2.6)	0	2 (22.2)	0	4 (3)
GIS + MSS	1 (1.6)	0	1 (5.9)	0	0	2 (1.5)
Face + CVS	0	1 (2.6)	0	0	0	1 (0.7)
Karyotype						
Refused	7 (10.9)	5 (12.8)	2 (11.8)	1 (11.1)	0	15 (11.1)
Normal	50 (70.8)	27 (69.2)	10 (58.8)	5 (55.5)	3 (50)	95 (70.4)
Abnormal	7 (10.9)	7 (17.9)	5 (29.4)	3 (33.3)	3 (50)	25 (18.5)
Trisomy 21	2 (3.1)	4 (10.3)	4 (23.5)	1 (11.1)	1 (16.7)	12 (8.9)
Trisomy 18	1 (1.6)	1 (2.6)	0	2 (22.2)	1 (16.7)	5 (3.7)
Other	4 (6.3)	2 (5.1)	1 (5.9)	0	1 (16.7)	8 (5.9)
Pregnancy outcome						
Abortion	6 (9.4)	4 (10.3)	2 (11.8)	3 (33.3)	1 (16.7)	16 (11.9)
TOP	5 (7.8)	4 (10.3)	4 (23.5)	2 (22.2)	4 (66.7)	19 (14.1)
IUFD	1 (1.6)	1 (2.6)	0	0	0	2 (1.5)
T and L	44 (68.8)	23 (59)	9 (52.9)	4 (44.4)	0	80 (59.3)
PD	2 (3.1)	3 (7.7)	1 (5.9)	0	0	6 (4.4)
PB	6 (9.4)	4 (10.3)	1 (5.9)	0	1 (16.7)	12 (8.9)

NT: Nuchal translucency, SD: Standard deviation, DV: Ductus venosus, CH: Cystic hygromas, CNS: Central nervous system, CVS: Cardiovascular system, GIS: Gastrointestinal system, MSS: Musculoskeletal system, NB: Nasal bone, SUA: Single umbilical artery, HF: Hydrops fetalis, M.M: Minor marker, TOP: Termination of pregnancy, IUFD: Intrauterine fetal death, T and L: Term and live birth, PD: Postnatal death, PB: Preterm delivery

There was a significant but a mild correlation between EJLS and NT (correlation coefficient [CC] =0.283), fetal abnormalities (CC =0.273), and adverse pregnancy outcomes (CC =0.308), ( $P < 0.05$ ). In addition, there was a significant correlation between NT and fetal anomalies (CC =0.404) and unfavorable pregnancy outcomes (CC =0.320), ( $P < 0.05$ ) [Table 5].

## DISCUSSION

The presence of EJLS was in 12.9% of all cases with increased NT, and 75% of fetuses in this group had abnormal anatomy, 45% had an abnormal karyotype, and only 15% achieved T and L birth. Compared to cases with EJLS, n-EJLS cases had better pregnancy outcomes, including lower rates of fetal structural and karyotypic abnormalities and higher rates of T and L.

However, the rate presence EJLS increased as NT increased, and this increase was more pronounced when NT  $\geq 4.5$  mm. In addition, there was an increased rate of fetal structural and karyotypic abnormalities and poor pregnancy outcome as NT increased which is making hard to detect the exact effect of EJLS on these outcomes. Nonetheless, in the presence of EJLS, this study provides practical information, particularly for those using elevated NT to predict fetal karyotypic and structural abnormalities and obstetric outcomes without further stratification.

We believe that if EJLS is associated with an increase in NT, this should be a warning sign that fetal anatomy and karyotype should be carefully examined, considering that 75% of them have structural abnormalities and almost half have karyotypic abnormalities.

**Table 3: Characteristics of cases with extended jugular lymphatic sac**

Variables	NT					Total cases (n=20), n (%)
	≥95 <sup>th</sup> percentile- 3.5 mm (n=3), n (%)	3.6-4.4 mm (n=4), n (%)	4.5-5.4 mm (n=7), n (%)	5.5-6.4 mm (n=4), n (%)	≥6.5 mm (n=2), n (%)	
Maternal age (mean±SD)	22±3.0	31.5±5.59	33.29±3.82	27.75±10.14	32±12.73	30±7.7
Gravida (mean±SD)	1.33±0.58	2±0.82	2.71±1.5	2.75±1.71	3.5±3.54	2.45±1.56
Reversed a wave in DV	1 (33.3)	2 (50)	1 (14.3)	1 (25)	1 (50)	6 (30)
Fetal anatomy						
Normal	1 (33.3)	1 (25)	0	0	0	2 (10)
Abnormal	2 (66.7)	1 (25)	7 (100)	4 (100)	1 (50)	15 (75)
M.M	0	2 (50)	0	0	1 (50)	3 (15)
Affected organ or systems						
CH	1 (33.3)	1 (25)	3 (42.9)	2 (50)	1 (50)	8 (40)
CNS	0	0	1 (14.3)	0	0	2 (10)
CVS	1 (33.3)	2 (50)	0	1 (25)	0	3 (15)
GIS	0	0	0	0	1 (50)	1 (5)
MSS	0	0	0	1 (25)	0	1 (5)
Isolated HF	0	0	3 (42.9)	0	0	3 (15)
Fetal karyotype						
Refused	1 (33.3)	0	1 (14.3)	1 (25)	1 (50)	4 (20)
Normal	1 (33.3)	0	3 (42.9)	2 (50)	1 (50)	7 (35)
Abnormal	1 (33.3)	4 (100)	3 (42.9)	1 (25)	0	9 (45)
Trisomy 21	0	3 (75)	3 (42.9)	1 (25)	0	7 (35)
Trisomy 18	0	1 (25)	0	0	0	1 (5)
Others	1 (33.3)	0	0	0	0	1 (5)
Pregnancy outcome						
Abortion	1 (33.3)	0	1 (14.3)	0	1 (50)	3 (15)
TOP	1 (33.3)	4 (100)	2 (28.6)	3 (75)	1 (50)	11 (55)
T and L	1 (33.3)	0	1 (14.3)	1 (25)	0	3 (15)
PD	0	0	2 (28.6)	0	0	2 (10)
PB	0	0	1 (14.3)	0	0	1 (5)

NT: Nuchal translucency, SD: Standard deviation, DV: Ductus venosus, CH: Cystic hygromas, CNS: Central nervous system, CVS: Cardiovascular system, GIS: Gastrointestinal system, MSS: Musculoskeletal system, HF: Hydrops fetalis, M.M: Minor marker, TOP: Termination of pregnancy, T and L: Term and live birth, PD: Postnatal death, PB: Preterm delivery

Indeed, this raises the question of whether EJLS is a cause or a result in cases with increased NT. The pathophysiology of enlarged NT has been discussed for four decades. It has been associated with many fetal structural or genetic abnormalities. Therefore, it is not thought to be caused by a single pathophysiological mechanism. Abnormalities in extracellular matrix composition, hemodynamic alterations in first trimester, and abnormal endothelial development due to several reasons have been the most accepted origins for enlarged NT.<sup>[6,7,13,19,20]</sup> Furthermore, it has been suggested that the pathophysiology of increased NT may be caused by a delayed reorganization of the lymph nodes. Lymphatic endothelial cell buds originate from the internal jugular veins and lymphatic development begins with the formation of JLS in the neck and forms the main drainage area for lymphatic fluid to enter the systemic circulation as the right thoracic duct grows toward the left JLS at 14 weeks of gestation.<sup>[20,21]</sup>

Similar to our study, existing studies reported a correlation between NT distance and presence of EJLS.<sup>[13,22,23]</sup> In agreement with a study by Bronshtein *et al.*, in which the authors attributed the pathophysiological basis of cystic hygroma to the failure of

the lymphatic system to communicate with the nuchal venous system, we observed that the most common accompanying abnormality to be cystic hygroma in increased NT cases both with and without EJLS.<sup>[24]</sup> Complete but delayed remodeling of the lymphatic system could explain both the regional and transient features of the increased NT and the high T and L birth rates found in this study, 59.3% in increased NT without EJLS. However, compared with this group, the fetuses with EJLS had a lower T and L birth rate, a higher rate of reversed a-wave in DV, and a higher rate of karyotypic and structural abnormalities. This may suggest another pathophysiological mechanism that endothelial signaling is crucial in embryogenesis and is involved in the processes of heart formation and blood and lymphatic vessel development. Indeed, processes in genes involved in endothelial differentiation may affect both cardiac and lymphatic vasculature, and it is likely that environmental, epigenetic, or genetic influences are responsible.<sup>[25,26]</sup>

In this study, there was a higher rate of reversed a-wave in DV when increased NT was accompanied by EJLS. In addition to the theory suggesting the aforementioned developmental pathophysiological mechanism of the DV, another theory

**Table 4: Comparison of outcomes between cases with and without extended jugular lymphatic sac**

Variables	Cases without EJLS (n=135), n (%)	Cases with EJLS (n=20), n (%)	P
Maternal age (mean±SD)	29.07±5.96	30±7.7	0.576***
Gravida (mean±SD)	2.38±1.44	2.45±1.56	0.962****
NT			
≥95 <sup>th</sup> percentile-3.5 mm	64 (47.4)	3 (15)	0.003*
3.6-4.4 mm	39 (28.9)	4 (20)	
4.5-5.4 mm	17 (12.6)	7 (35)	
5.5-6.4 mm	9 (6.7)	4 (20)	
≥6.5 mm	6 (4.4)	2 (10)	
Reversed a wave in DV	14 (10.4)	6 (30)	0.026*
Fetal anatomy			
Normal	66 (48.9)	2 (10)	0.003**
Abnormal	52 (38.5)	15 (75)	
M.M	17 (12.6)	3 (15)	
Fetal karyotype			
Refused	15 (11.1)	4 (20)	0.005**
Normal	95 (70.4)	7 (35)	
Abnormal	25 (18.5)	9 (45)	
Trisomy 21	12 (8.9)	7 (35)	
Trisomy 18	5 (3.7)	1 (5)	
Others	8 (5.9)	1 (5)	
Pregnancy outcome			
Abortion	16 (11.9)	3 (15)	<0.001**
TOP	19 (14.1)	11 (55)	
IUFD	2 (1.5)	0	
T and L	80 (59.3)	3 (15)	
PD	6 (4.4)	2 (10)	
PB	12 (8.9)	1 (5)	

\*Fisher's exact test, \*\*Chi-square test, \*\*\*t-test, \*\*\*\*Mann-Whitney test.  $P<0.05$  considered as significance. NT: Nuchal translucency, EJLS: Extended jugular lymphatic sac, SD: Standard deviation, DV: Ductus venosus, M.M: Minor marker, TOP: Termination of pregnancy, IUFD: Intrauterine fetal death, T and L: Term and live birth, PD: Postnatal death, PB: Preterm delivery

**Table 5: Spearman-Rho correlations between extended jugular lymphatic sac, nuchal translucency, fetal abnormalities, and adverse pregnancy outcomes**

Spearman Rho	Variables	CC	P
EJLS	NT	0.283	<0.001
	Fetal abnormalities	0.271	0.001
	Adverse pregnancy outcomes	0.308	<0.001
NT	EJLS	0.283	<0.001
	Fetal abnormalities	0.404	<0.001
	Adverse pregnancy outcomes	0.320	<0.001

$P<0.05$  considered as significance. EJLS: Extended jugular lymphatic sac, NT: Nuchal translucency, CC: Correlation coefficient

indicated that high venous pressure due to EJLS, abnormal innervation of the jugular vein, and DV may contribute to abnormal flow rates in fetuses with elevated NT.<sup>[22]</sup>

In this study, cystic hygromas (40%), isolated hydrops fetalis (15%), and cardiovascular abnormalities (15%) were the most common abnormalities noted in EJLS cases. Among these, being specific organ anomalies, the cardiovascular anomalies had the highest rate of poor obstetric outcome and abnormal karyotype. In the n-EJLS group, the most common

abnormalities were cystic hygromas (27%), cardiovascular (15%), and gastrointestinal system (9%) anomalies. Our results are consistent with previous studies that found cystic hygromas and hydrops fetalis to be the most frequently observed abnormalities in EJLS cases. Considering the increased NT, our results seem to differ from studies that described cardiovascular and musculoskeletal abnormalities as the first two most common abnormalities both with and without EJLS.<sup>[4,27]</sup>

We found a higher rate of abnormal fetal karyotypes in cases with EJLS (45%) than in those without EJLS (18.5%). The most frequently detected abnormal karyotype in both groups, trisomy 21, was more common in cases with EJLS than in cases without EJLS (77% and 48%, respectively). The study by Haak *et al.* reported that the development of EJLS preceded the increase of NT in mouse embryos with trisomy 16, which is the animal model for trisomy 21 in humans.<sup>[23]</sup> Therefore, EJLS may be a more specific finding than increased NT, as there are more pathophysiological pathways leading to increased NT, as mentioned previously.<sup>[4,25-27]</sup>

The rate of T and L births was much higher in cases without EJLS (59.3%) compared with those with EJLS (15%). This

may be due, in part, to the higher frequency of normal fetal anatomy and karyotype in the former. For example, we observed that when fetal anatomy was normal, the rate of T and L birth was 73% in cases without EJLS and 66% in cases with EJLS. Similar to our study, positive pregnancy outcomes were reported in 50%–71% of cases with increased NT between 4.5 and 5.4 mm with normal fetal anatomy.<sup>[16]</sup>

Although studies showed the occurrence of early childhood developmental delays in up to 9% of such cases.<sup>[15]</sup> Senat *et al.* reported that no fetal structural malformations occur when the karyotype is normal and that when nuchal translucency (NT) improves, prognosis at 2 years of age is not affected.<sup>[28]</sup> However, similar to our study, increased NT is known to adversely affect pregnancy outcomes even in fetuses with normal karyotype and anatomy, particularly by reducing viable pregnancy rates above 3.5 mm.<sup>[15]</sup>

There are strengths in this study, although both examination and clinical management were performed by the same team. However, whether it can be classified as a research feature is still a question. Because the same team is also more prone to specific recommendations. The authors are advised to include the features of this study.

Weaknesses of this study: First, that patient selection was variable in some situations, including fetal structural and karyotypic abnormalities, that may affect rates of miscarriage, TOP or preterm birth, and T and L. Second, because of the relatively small number of patients in each NT stratum, we could not demonstrate the exact risk added by EJLS on NT. This was another limitation due to the wide range of data and the difficulty in presenting them, as each fetus undergoes its process in a unique way.

## CONCLUSION

The rate of EJLS became higher with increasing NT and the majority of EJLS cases NT had  $\geq 4.5$  mm. Cases with EJLS were more likely to have poor pregnancy outcome, abnormal karyotype, and structural abnormalities. The most common structural and karyotypic abnormalities detected were cystic hygromas and trisomy 21 in both groups, with and without EJLS, with both being more pronounced in EJLS.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy. *BMJ* 1992;304:867-9.
- Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. *Lancet* 1998;352:343-6.
- Timmerman E, Pajkrt E, Maas SM, Bilardo CM. Enlarged nuchal translucency in chromosomally normal fetuses: Strong association with orofacial clefts. *Ultrasound Obstet Gynecol* 2010;36:427-32.
- Tekeşin I. Pregnancy outcome in foetuses with increased nuchal translucency - 10-years' experience in a prenatal medical practice. *J Obstet Gynaecol* 2020;40:455-60.
- Montenegro N, Matias A, Areias JC, Castedo S, Barros H. Increased fetal nuchal translucency: Possible involvement of early cardiac failure. *Ultrasound Obstet Gynecol* 1997;10:265-8.
- Holzer I, Husslein PW, Bettelheim D, Scheidl J, Kiss H, Farr A. Value of increased nuchal translucency in the era of noninvasive prenatal testing with cell-free DNA. *Int J Gynaecol Obstet* 2019;145:319-23.
- Haak MC, van Vugt JM. Pathophysiology of increased nuchal translucency: A review of the literature. *Hum Reprod Update* 2003;9:175-84.
- van Heesch PN, Struijk PC, Brandenburg H, Steegers EA, Wildschut HI. Jugular lymphatic sacs in the first trimester of pregnancy: The prevalence and the potential value in screening for chromosomal abnormalities. *J Perinat Med* 2008;36:518-22.
- Sharon R, Tepper R, Fejgin M. Fetal lateral neck cysts: The significance of associated findings. *Prenat Diagn* 2005;25:507-10.
- Bronshstein M, Bar-Hava I, Blumenfeld I, Bejar J, Toder V, Blumenfeld Z. The difference between septated and nonseptated nuchal cystic hygroma in the early second trimester. *Obstet Gynecol* 1993;81:683-7.
- Turner CJ, Badu-Nkansah K, Crowley D, van der Flier A, Hynes RO. Integrin- $\alpha 5\beta 1$  is not required for mural cell functions during development of blood vessels but is required for lymphatic-blood vessel separation and lymphovenous valve formation. *Dev Biol* 2014;392:381-92.
- Ohga A, Sakamoto R, Yamada S, Takakuwa T. Vesicular swelling in the cervical region with lymph sac formation in human embryos. *Congenit Anom (Kyoto)*. 2019 May 18.
- Bekker MN, Haak MC, Rekoert-Hollander M, Twisk J, Van Vugt JM. Increased nuchal translucency and distended jugular lymphatic sacs on first-trimester ultrasound. *Ultrasound Obstet Gynecol* 2005;25:239-45.
- Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH. Relation between increased fetal nuchal translucency thickness and chromosomal defects. *Obstet Gynecol* 2006;107:6-10.
- Souka AP, Kramp E, Bakalis S, Heath V, Nicolaides KH. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. *Ultrasound Obstet Gynecol* 2001;18:9-17.
- Bilardo CM, Müller MA, Pajkrt E, Clur SA, van Zalen MM, Bijlsma EK. Increased nuchal translucency thickness and normal karyotype: Time for parental reassurance. *Ultrasound Obstet Gynecol* 2007;30:11-8.
- Michailidis GD, Economides DL. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. *Ultrasound Obstet Gynecol* 2001;17:102-5.
- Shakoor S, Dileep D, Tirmizi S, Rashid S, Amin Y, Munim S. Increased nuchal translucency and adverse pregnancy outcomes. *J Matern Fetal Neonatal Med* 2017;30:1760-3.
- Gittenberger-De Groot AC, Van Den Akker NM, Bartelings MM, Webb S, Van Vugt JM, Haak MC. Abnormal lymphatic development in trisomy 16 mouse embryos precedes nuchal edema. *Dev Dyn* 2004;230:378-84.
- Sebire NJ, D'Ercole C, Hughes K, Carvalho M, Nicolaides KH. Increased nuchal translucency thickness at 10-14 weeks of gestation as a predictor of severe twin-to-twin transfusion syndrome. *Ultrasound Obstet Gynecol* 1997;10:86-9.
- Liang D, Chang JR, Chin AJ, Smith A, Kelly C, Weinberg ES, *et al.* The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development. *Mech Dev* 2001;108:29-43.
- van der Putte SC. The development of the lymphatic system in man. *Adv Anat Embryol Cell Biol* 1975;51:3-60.
- Haak MC, Bartelings MM, Jackson DG, Webb S, van Vugt JM, Gittenberger-de Groot AC. Increased nuchal translucency is associated with jugular lymphatic distension. *Hum Reprod* 2002;17:1086-92.
- Bronshstein M, Rottem S, Yoffe N, Blumenfeld Z. First-trimester and early second-trimester diagnosis of nuchal cystic hygroma by transvaginal sonography: Diverse prognosis of the septated from the

- nonseptated lesion. *Am J Obstet Gynecol* 1989;161:78-82.
25. Cleaver O, Melton DA. Endothelial signaling during development. *Nat Med* 2003;9:661-8.
26. Burger NB, Bekker MN, de Groot CJ, Christoffels VM, Haak MC. Why increased nuchal translucency is associated with congenital heart disease: A systematic review on genetic mechanisms. *Prenat Diagn* 2015;35:517-28.
27. Eckmann-Scholz C, Salmassi A, Jonat W, Alkatout I. Distended jugular lymphatic sacs in fetuses with increased nuchal translucency: Correlation with first-trimester findings in aberrant karyotypes. *J Matern Fetal Neonatal Med* 2014;27:257-60.
28. Senat MV, Bussières L, Couderc S, Roume J, Rozenberg P, Bouyer J, *et al.* Long-term outcome of children born after a first-trimester measurement of nuchal translucency at the 99<sup>th</sup> percentile or greater with normal karyotype: A prospective study. *Am J Obstet Gynecol* 2007;196: 6.e1-6.